Latest Medication News

Pfizer signs are seen out front of the Pfizer Research & Development Laboratories Wednesday, July 22, 2020, in Groton, Conn.  Pfizer on Tuesday, July 28,  reported a 32% plunge in second-quarter profit, as the global coronavirus pandemic limited marketing of and new prescriptions for its medicines. Still, the biggest U.S. drugmaker posted a solid profit and nudged up parts of its 2020 financial forecast. (AP Photo/Stew Milne)

Pfizer tops 3Q earnings views, makes progress on COVID shot

Oct. 27, 2020 5:12 PM EDT

Drugmaker Pfizer, one of the leaders in the race to develop a COVID-19 vaccine, is tweaking its timeline for when it will know if its experimental two-dose vaccine works. Pfizer executives had expected data from their 44,000-person international study would show by Oct. 31 how well it prevents coronavirus...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J.  Surging sales of cancer medicines and reduced spending helped Merck overcome a big hit from the coronavirus pandemic and increase its profit 12% in the second quarter. The  drugmaker on Friday, July 31, 2020,  increased its financial forecast for the year, all while it’s investing in development of two experimental vaccines and a possible treatment for COVID-19.  (AP Photo/Seth Wenig, File)

Strong sales of drugs, vaccines, propel Merck in 3Q

Oct. 27, 2020 3:09 PM EDT

Drugmaker Merck, bouncing back from a $1.6 billion hit from the coronavirus pandemic in the second quarter, boosted its third-quarter profit by 55% and blew past Wall Street expectations. The strong result was due to sales slightly higher than a year ago, plus restrained spending. The Kenilworth, New Jersey,...

FILE - This is an April 26, 2017, file photo showing Eli Lilly corporate headquarters in Indianapolis. Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients. The drugmaker said Tuesday, Oct. 27, 2020, that It remains confident that its drug may stop COVID from developing in other patients. (AP Photo/Darron Cummings, File)

Lilly stays confident in possible COVID drug after setback

Oct. 27, 2020 11:35 AM EDT

INDIANAPOLIS (AP) — Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients. The drugmaker said Tuesday it remains confident that its drug may stop COVID from developing in other patients. Researchers are still studying the drug in...

En esta imagen de mayo de 2020 distribuida por Eli Lilly, un investigador prueba posibles anticuerpos de COVID-19 en un laboratorio de Indianápolis. (David Morrison/Eli Lilly via AP, Archivo)

Lilly misses profit projects as sales of diabetes drug slow

Oct. 27, 2020 7:09 AM EDT

INDIANAPOLIS (AP) — Eli Lilly and Co. is reporting third-quarter net income of $1.21 billion. On a per-share basis, the Indianapolis company said it had profit of $1.33. Earnings, adjusted for asset impairment costs, were $1.54 per share. That's far short of the per-share earnings of $1.76 that Wall Street...

FILE - This Tuesday, Aug. 15, 2017 file photo shows an arrangement of pills of the opioid oxycodone-acetaminophen in New York. On Monday, Oct. 26, 2020, the American Academy of Pediatrics issued new guidance aimed at improving care for women and newborns affected by the mothers’ opioid use. (AP Photo/Patrick Sison)

New guidelines address rise in opioid use during pregnancy

Oct. 26, 2020 3:59 PM EDT

Opioid use in pregnancy has prompted new guidance from the American Academy of Pediatrics, aimed at improving care for women and newborns affected by their mothers’ drug use. The number of affected women and infants has increased in recent years but they often don’t get effective treatment, and the...

FILE - In this Oct. 16, 2015 file photo, Jonathan Hunt, vice president of Monarch America, Inc., shows a marijuana plant while giving a tour of the Flandreau Santee Sioux Tribe's marijuana growing facility, in Flandreau, S.D. Voters in four states could embrace broad legal marijuana sales on Election Day, setting the stage for a watershed year for the industry that could snowball into neighboring states as well as reshape policy on Capitol Hill. The Nov. 3, 2020, contests will take place in markedly different regions of the country, New Jersey, Arizona, South Dakota and Montana and approval of the proposals would highlight how public acceptance of cannabis is cutting across geography, demographics and the nation's deep political divide. (Joe Ahlquist/The Argus Leader via AP, File)

Election could stoke US marijuana market, sway Congress

Oct. 25, 2020 11:10 AM EDT

Voters in four states from different regions of the country could embrace broad legal marijuana sales on Election Day, and a sweep would highlight how public acceptance of cannabis is cutting across geography, demographics and the nation’s deep political divide. The Nov. 3 contests in New Jersey, Arizona,...

FILE - In this March 2020 photo provided by Gilead Sciences, rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States. On Thursday, Oct. 22, 2020, the U.S. Food and Drug Administration has approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given through an IV for patients needing hospitalization. The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days on average in a large study led by the U.S. National Institutes of Health. (Gilead Sciences via AP)

FDA approves first COVID-19 drug: antiviral remdesivir

Oct. 22, 2020 5:40 PM EDT

U.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalized patients through an IV. The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in...

Long lines as Missouri medical marijuana dispensaries open

Oct. 21, 2020 12:33 PM EDT

ST. LOUIS (AP) — Missouri's first licensed marijuana dispensaries opened this weekend in the St. Louis area with long lines. The two dispensaries run by N'Bliss opened Saturday in Ellisville and Manchester. Another dispensary is expected to open Monday in the Kansas City area nearly two years after...

FILE - In this Thursday, April 30, 2020 file photo, Health care workers look on during a flyover at the University of Utah Hospital in Salt Lake City. One of Utah's largest hospitals had no beds left Friday, Oct. 16, 2020 in its regular intensive-care unit as the governor declared the state's weeks long spike in coronavirus cases

The Latest: New Mexico sets another one-day COVID-19 record

Oct. 16, 2020 8:09 PM EDT

ALBUQUERQUE, N.M. -- New Mexico health officials on Friday confirmed the state set another single-day record with 819 COVID-19 cases, bringing the statewide total to 35,770 since the pandemic began. New rules to limit gatherings to five people or less, reduce hotel capacities and impose a 10 p.m. closing time for...

A bottle containing the drug Remdesivir is held by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary, Thursday Oct. 15, 2020. A large study led by the World Health Organization released on Friday, Oct. 16, 2020, suggests that the antiviral drug did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries. The results do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival. (Zsolt Czegledi/MTI via AP)

WHO study finds remdesivir didn't help COVID-19 patients

Oct. 16, 2020 11:47 AM EDT

GENEVA (AP) — A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries. The results announced Friday do...